doi: 10.1038/s41581-018-0018-2 178 YiannopoulouK
Vildagliptin (LAF237, Novartis International AG, Basel, Switzerland), a cyanopyrrolidide-based DPP-IV inhibitor, also in late stage clinical development, has been reported to reduce fasting and postprandial glucose concentrations
This supplement can cause serious side effects
Dapagliflozin A total of 1424 (24%) of the 5936 dapagliflozin-treated patients were 65 years and older and 207 (3.5%) patients were 75 years and older in a pool of 21 double-blind, controlled, clinical trials assessing the efficacy of dapagliflozin in improving glycemic control
You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter (and the work that goes into it!) and get special benefits
Its really not pleasant at all